Get notified of page updates

Cancer Treatment: Types of Biomarker Tests

Learn about the different tests can help guide treatment. Stay up to date by signing up for our community newsletter.

Risk Management & Treatment > Cancer Treatment > Biomarker Testing > Cancer Treatment: Types of Biomarker Tests

Glossary on
off

Biomarkers Used for Treatment Selection

The following biomarkers may be used to select treatment for cancer. This is not a complete list of all biomarkers and available treatments. Additional biomarkers may be used to for clinical research studies. Speak with your doctor about additional testing which may help guide your treatment.

Biomarker

Cancers

Treatment

  • AKT1, PIK3 or PTEN mutation
  • Breast
  • Truqap (capivasertib)
  • BRAFV600E
  • Colorectal
  • Melanoma
  • BRAF inhibitors
  • BRCA1
  • BRCA2
  • Breast
  • Ovarian
  • Pancreatic
  • Prostate
  • PARP inhibitors
  • Epidermal growth factor receptor (EGFR)
  • Colorectal
  • EGFR inhibitors
  • ESR1 mutation
  • Breast
  • Oserdu (elacestrant)
  • Positive for FRα (folate receptor-alpha)
  • Ovarian
  • Elahere (mirvetuximab soravtansine)
  • Hormone receptor-positive (HR-positive)
  • Estrogen/progesterone receptor-positive (ER/PR-positive)
  • Breast
  • Endometrial
  • Aromatase inhibitors (AIs)
  • CDK4/6 inhibitors
  • Selective estrogen receptor degraders (SERDs)
  • Selective estrogen receptor modulators (SERMs)
  • HER2-positive
  • Breast
  • Colorectal
  • Pantumor (Enhertu)
  • Anti-HER2 therapies
  • Tukysa (tucatinib)
  • HER2-low
  • Breast
  • Enhertu (trastuzumab deruxtecan)
  • Homologous recombination deficiency (HRD)
  • Ovarian
  • Lynparza (olaparib)
  • Lynparza and Avastin (bevacizumab)
  • Homologous recombination repair (HRR) gene mutations (tumor mutations in the following genes):
    • ATM, BARD1, BRCA1, BRCA2, BRIP1, CDK12, CHEK2, FANCA, FANCL, MLH1, PALB2, RAD51B, RAD51C, RAD51D, MRE11A or NBN
  • Prostate
  • Talzenna (talazoparib) and Xtandi (enzalutamide)
  • KRAS or NRAS mutation
  • Colorectal
  • Melanoma
  • EGFR inhibitors
  • Microsatellite instability-high (MSI-H)
  • Mismatch repair deficient (dMMR or MMR-D)
  • Colorectal
  • Endometrial
  • Pan-tumor
  • Immune checkpoint inhibitors
  • NTRK fusion
  • Pan-tumor
  • Vitrakvi (larotrectinib)
  • PD-L1 positive
  • Breast
  • Tecentriq (atezolizumab)
  • PIK3CA mutation
  • Breast
  • Piqray (alpelisib)
  • RET gene fusion
  • Pan-tumor
  • Retevmo (Selpercatinib)
  • TMB-H (Tumor mutational burden-high)
  • Pan-tumor
  • Keytruda (pembrolizumab)
Last updated November 17, 2024